The DOI matches its Crossref record; 25 of the 27 references it cites were found in a registry or an index.
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes
Open accessAbstract
OBJECTIVE—The Treating to New Targets study showed that intensive lipid-lowering therapy with atorvastatin 80 mg/day provides significant clinical benefit beyond that afforded by atorvastatin 10 mg/day in patients with stable coronary heart disease (CHD). The objective of our study was to investigate whether similar benefits of high-dose intensive atorvastatin therapy can be achieved in patients with CHD and diabetes. RESEARCH DESIGN AND METHODS—A total of 1,501 patients with diabetes and CHD, with LDL cholesterol levels of <130 mg/dl, were randomized to double-blind therapy with either atorvastatin 10 (n = 753) or 80 (n = 748) mg/day. Patients were followed for a median of 4.9 years. The primary end point was the time to first major cardiovascular event, defined as death from CHD, nonfatal non–procedure-related myocardial infarction, resuscitated cardiac arrest, or fatal or nonfatal stroke. RESULTS—End-of-treatment mean LDL cholesterol levels were 98.6 mg/dl with atorvastatin 10 mg and 77.0 mg/dl with atorvastatin 80 mg. A primary event occurred in 135 patients (17.9%) receiving atorvastatin 10 mg, compared with 103 patients (13.8%) receiving atorvastatin 80 mg (hazard ratio 0.75 [95% CI 0.58–0.97], P = 0.026). Significant differences between the groups in favor of atorvastatin 80 mg were also observed for time to cerebrovascular event (0.69 [0.48–0.98], P = 0.037) and any cardiovascular event (0.85 [0.73–1.00], P = 0.044). There were no significant differences between the treatment groups in the rates of treatment-related adverse events and persistent elevations in liver enzymes. CONCLUSIONS—Among patients with clinically evident CHD and diabetes, intensive therapy with atorvastatin 80 mg significantly reduced the rate of major cardiovascular events by 25% compared with atorvastatin 10 mg.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subgroup analyses of people with diabetes in larger trials (101-105) and trials in people with diabetes (106,107) showed significant primary and secondary prevention of ASCVD events and CHD death in people with diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [104]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subgroup analyses of people with diabetes in larger trials (94–98) and trials in people with diabetes (99,100) showed significant primary and secondary prevention of ASCVD events and coronary heart disease (CHD) death in people with diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [97]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although statins are efficacious in patients with type 2 diabetes, rates of cardiovascular events remain elevated in such patients even after statin treatment.7–9”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [8]
In the citing paper
“Lipid profile has long been considered among the most important risk factors for CVD in T2DM, and several trials have confirmed that lowering low-density lipoprotein cholesterol (LDL-C) via statins in T2DM was effective in reducing the risk of CVD [81, 82].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [82]
In the citing paper
“A subgroup analysis of 1501 diabetic patients included in the Treating to New Targets (TNT) study, which compared intensive statin therapy (atorvastatin 80 mg) with standard statin therapy (atorvastatin 10 mg), showed a reduction in risk of primary events, cerebrovascular events, and all cardiovascular events in patients in the intensive statin therapy group.442”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [442]
In the citing paper
“These recommendations are based on the observation that high-intensity versus moderate-intensity statin therapy reduces cardiovascular event rates in high-risk individuals with established cardiovascular disease in randomized trials (95,107).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [95]
In the citing paper
“Subgroup analyses of people with diabetes in larger trials (92 -96) and trials in people with diabetes (97,98) showed signi fi cant primary and secondary prevention of ASCVD events and CHD death in people with diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [95]
In the citing paper
“For patients with a myocardial infarction history, it has been reported that the risk of recurrence of cardiovascular events increases with the presence of diabetes137, 749–751).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [751]
In the citing paper
“According to a meta-analysis by the Cholesterol Treatment Trialists' (CTT) Collaboration, the effects of LDL-C-lowering therapy using statins on cardiovascular event are equal regardless of whether the patient had diabetes751).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [751]
In the citing paper
“These effects were similar to those in nondiabetic subjects751).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [751]
In the citing paper
“Subanalyses of diabetic subgroups of larger trials (186–190) and trials specifically in subjects with diabetes (191,192) showed significant primary and secondary prevention of CVD events ± CHD deaths in diabetic populations.”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [189]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Self-citationExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citation
Flagged first, then by citations
2 of the 27 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 525
Chamberlain, J. J., Johnson, E. L., Leal, S., Rhinehart, A. S., Shubrook, J. H., & Peterson, L. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0222 · Cited by 105
Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Steinberg, D. H., Glass, C. K., & Witztum, J. L. (2008) · Circulation · doi:10.1161/circulationaha.107.753152 · Cited by 102
Watts, G. F., & Karpe, F. (2011) · Heart · doi:10.1136/hrt.2010.204990 · Cited by 97
Jenkins, D. J. A., Kendall, C. W. C., Vuksan, V., Faulkner, D., Augustin, L. S. A., Mitchell, S., Ireland, C., Srichaikul, K., Mirrahimi, A., Chiavaroli, L., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2990 · Cited by 91
Settergren, M., Böhm, F., Rydén, L., & Pernow, J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn166 · Cited by 90
PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016
Banach, M., Jankowski, P., Jóźwiak, J., Cybulska, B., Windak, A., Guzik, T., Mamcarz, A., Broncel, M., & Tomasik, T. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64712 · Cited by 86
Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease
Krenning, G., Dankers, P. Y. W., Drouven, J. W., Waanders, F., Franssen, C. F. M., van Luyn, M. J. A., Harmsen, M. C., & Popa, E. R. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90755.2008 · Cited by 85
The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus
Elam, M. B., Lovato, L., & Ginsberg, H. N. (2011) · Clinical Lipidology · doi:10.2217/clp.10.84 · Cited by 88
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes—the CORALL study
Şimşek, S., Schalkwijk, C., & Wolffenbuttel, B. H. R. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03553.x · Cited by 83
Krempf, M., Parhofer, K. G., Steg, P. G., Bhatt, D. L., Ohman, E. M., Röther, J., Goto, S., Pasquet, B., & Wilson, P. W. F. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.048 · Cited by 82
The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial
Ginsberg, H. N. (2011) · Diabetes Care · doi:10.2337/dc11-s203 · Cited by 80
Saroglitazar for the treatment of dyslipidemia in diabetic patients
Joshi, S. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1009894 · Cited by 81
Dyslipidemia in type 2 diabetes mellitus
Gadi, R., & Samaha, F. F. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0036-0 · Cited by 78
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010024 · Cited by 77
Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus
Bangalore, S., Fayyad, R. S., DeMicco, D. A., Colhoun, H. M., & Waters, D. D. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004724 · Cited by 77
Self-citationDo we need to consider inflammatory markers when we treat atherosclerotic disease?
Athyros, V. G., Kakafika, A. I., Karagiannis, A. I., & Mikhailidis, D. P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.026 · Cited by 75
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 81
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors
Cho, Y., Choe, E.-Y., Lee, Y., Seo, J. W., Choi, Y., Yun, Y., Wang, H. J., Ahn, C. W., Soo, B., Lee, H. C., et al. (2014) · Metabolism · doi:10.1016/j.metabol.2014.09.008 · Cited by 73
ALDH2 genetic polymorphism and the risk of type II diabetes mellitus in CAD patients
Xu, F., Chen, Y., Lv, R., Zhang, H., Tian, H., Bian, Y., Feng, J., Sun, Y., Li, R., Wang, R., et al. (2009) · Hypertension Research · doi:10.1038/hr.2009.178 · Cited by 73
Authors Task Force Members, Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., et al. (2007) · European Heart Journal Supplements · doi:10.1093/eurheartj/ehl261 · Cited by 76
Shepherd, J., Kastelein, J. J. P., Bittner, V., Carmena, R., DEEDWANIA, P. C., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A. L., & WENGER, N. K. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.8.870 · Cited by 71
Self-citationAmerican Diabetes Association Indications for Statins in Diabetes
Eldor, R., & Raz, I. (2009) · Diabetes Care · doi:10.2337/dc09-s345 · Cited by 71
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.019 · Cited by 70
LaRosa, J. C., DEEDWANIA, P. C., Shepherd, J., WENGER, N. K., Greten, H., DeMicco, D. A., & Breazna, A. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.025 · Cited by 66
Self-citationMoreno, G., & Mangione, C. M. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12513 · Cited by 65
Blom, D. J., Koren, M. J., Roth, E. M., Monsalvo, M. L., Djedjos, C. S., Nelson, P., Elliott, M., Wasserman, S. M., Ballantyne, C. M., & Holman, R. R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12788 · Cited by 64
Hyperglycaemia and cardiovascular disease
Bartnik, M., Norhammar, A., & Rydén, L. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01831.x · Cited by 64
Howard, W. J. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79121-2 · Cited by 62
Generaux, G. T., Bonomo, F., Johnson, M., & Doan, K. M. M. (2011) · Xenobiotica · doi:10.3109/00498254.2011.562566 · Cited by 61
Statins and Protein Prenylation in Cancer Cell Biology and Therapy
García‐Ruiz, C., Morales, A., & Fernández-Checa, J. C. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012800228715 · Cited by 61
Combination statin-fibrate therapy: safety aspects
Franssen, R., Vergeer, M., Stroes, E. S. G., & Kastelein, J. J. P. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00917.x · Cited by 60
Prevalence and Treatment of Low HDL Cholesterol Among Primary Care Patients With Type 2 Diabetes
Grant, R. W., & Meigs, J. B. (2007) · Diabetes Care · doi:10.2337/dc06-1961 · Cited by 60
Raja-Khan, N. T., Kunselman, A. R., Hogeman, C. S., Stetter, C., Demers, L. M., & Legro, R. S. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.11.040 · Cited by 59
Milionis, H. J., Moutzouri, E., Kei, & Elisaf, M. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5593 · Cited by 59
Olafsdottir, E., Aspelund, T., Sigurðsson, G., Þórsson, B., Eiríksdóttir, G., Harris, T. B., Launer, L. J., Benediktsson, R., & Gudnason, V. G. (2011) · BMJ Open · doi:10.1136/bmjopen-2011-000132 · Cited by 59
Kuznik, A., & Mardekian, J. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-31 · Cited by 59
Preiss, D., Sattar, N. A., & McMurray, J. J. V. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.10.019 · Cited by 60
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 59
Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective
Elam, M. B., Lovato, L., & Ginsberg, H. N. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328341a5a8 · Cited by 56
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55
de Vries, F. M., Kolthof, J., Postma, M. J., Denig, P., & Hak, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111247 · Cited by 56
Guo, J., Meng, F., Ma, N., Li, C., Ding, Z., Wang, H., Hou, R., & Qin, Y. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.06.050 · Cited by 53
Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives
Sander, D., & Kearney, M. T. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5143-1 · Cited by 52
Zhang, X., Chen, J., Wang, H., & Yang, D. (2024) · Applied Geography · doi:10.1016/j.apgeog.2024.103472 · Cited by 51
Rosenson, R. S., Davidson, M. H., & Pourfarzib, R. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.03.038 · Cited by 51
Jahangiri-Noudeh, Y., Akbarpour, S., Lotfaliany, M., Zafari, N., Khalili, D., Tohidi, M., Mansournia, M. A., Azizi, F., & Hadaegh, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112639 · Cited by 51
Li, S., Flint, A., Pai, J. K., Forman, J. P., Hu, F. B., Willett, W. C., Rexrode, K. M., Mukamal, K. J., & Rimm, E. B. (2014) · BMJ · doi:10.1136/bmj.g2659 · Cited by 53
Who should receive a statin these days? Lessons from recent clinical trials
SHEPHERD, J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01700.x · Cited by 50
Self-citationUpdate on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
Diabetes and Cardiovascular Disease Prevention in Older Adults
Cigolle, C. T., Blaum, C. S., & Halter, J. B. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.09.001 · Cited by 50
Nelson, A. J., Ardissino, M., Haynes, K., Shambhu, S., Eapen, Z. J., McGuire, D. K., Carnicelli, A., Lópes, R. D., Green, J. B., O'Brien, E. C., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.016835 · Cited by 55
Inhibition of hepatic sulfatase-2 In Vivo : A novel strategy to correct diabetic dyslipidemia
Hassing, C., Mooij, H. L., Guo, S., Monia, B. P., Chen, K., Kulik, W., Dallinga‐Thie, G. M., Nieuwdorp, M., Stroes, E. S. G., & Williams, K. J. (2012) · Hepatology · doi:10.1002/hep.25580 · Cited by 56
Patterns and predictors of statin prescription in patients with type 2 diabetes
Berthold, H. K., Gouni‐Berthold, I., Böhm, M., Krone, W., & Bestehorn, K. P. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-25 · Cited by 49
Sharma, R. K. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5684 · Cited by 50
Cardiovascular and Metabolic Risk Factors: How Can We Improve Outcomes in the High-Risk Patient?
Grundy, S. M. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.06.005 · Cited by 48
Self-citationMelmer, A., & Laimer, M. W. (2016) · Endocrine development · doi:10.1159/000439364 · Cited by 53
Rosenson, R. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.010 · Cited by 48
Lipid control in patients with diabetes mellitus
Betteridge, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.23 · Cited by 48
Newman, C. B., Szarek, M. J., Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., DeMicco, D. A., Auster, S. B., & Fuller, J. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.029 · Cited by 48
Management of dyslipidemia in people with type 2 diabetes mellitus
Dunn, F. L. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9132-6 · Cited by 43
Identifying Patients for Aggressive Cholesterol Lowering: The Risk Curve Concept
Robinson, J. G., & Stone, N. J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.06.039 · Cited by 44
Fruchart, J., Sacks, F. M., Hermans, M. P., & on behalf of the International Steering Committee of Ri (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.489341 · Cited by 44
Self-citationBarakat, L., Jayyousi, A., Bener, A., Zuby, B., & Zirie, M. A. (2013) · ISRN Pharmacology · doi:10.1155/2013/146579 · Cited by 44
Drexel, H., Aczél, S., Marte, T., Vonbank, A., & Saely, C. H. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.08.026 · Cited by 42
Athyros, V. G., Katsiki, N., Τζιόμαλος, Κ., Gossios, T. D., Theocharidou, E., Gkaliagkousi, E., Anagnostis, P. G., Pagourelias, E. D., Karagiannis, A. I., & Mikhailidis, D. P. (2013) · Archives of Medical Science · doi:10.5114/aoms.2013.35424 · Cited by 42
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 44
The epidemiological concept of residual risk
Vanuzzo, D. (2011) · Internal and Emergency Medicine · doi:10.1007/s11739-011-0669-5 · Cited by 41
Lorenzatti, A. J., Eliaschewitz, F. G., Chen, Y., Lu, J., Baass, A. W., Monsalvo, M. L., Wang, N., Hamer, A. W., & Ge, J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13680 · Cited by 41
Goldfine, A. B. (2008) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32830c6c37 · Cited by 41
Perspectives on low-density-lipoprotein cholesterol goal achievement
Catapano, A. L. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802631438 · Cited by 40
Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus
Salvadó, L., Serrano, L., Barroso, E., Palomer, X., & Vázquez‐Carrera, M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.658370 · Cited by 42
All-cause and CVD mortality in Native Hawaiians
Aluli, N. E., Reyes, P. W., Brady, S. K., Tsark, J. '., Jones, K. L., Mau, M. L. M., Howard, W. J., & Howard, B. V. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.03.003 · Cited by 40
Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. N., Викторович, А. М., Алексеева, Л. И., Almazova, I. I., Andreenko, Е. Y., Antipushina, D. N., Balanova, Y. А., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3996 · Cited by 55
Wallach‐Kildemoes, H., Vass, M., Hendriksen, C., & Andersen, M. T. (2012) · Health Policy · doi:10.1016/j.healthpol.2012.08.008 · Cited by 37
Cardiorespiratory Fitness, LDL Cholesterol, and CHD Mortality in Men
Farrell, S. W., Finley, C. E., & Grundy, S. M. (2012) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31826524be · Cited by 42
Self-citationThe Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update
Katsiki, N., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660673 · Cited by 37
Huang, Q. B., Aa, J., Jia, H., Xin, X., Tao, C., Liu, L., Zou, B., Song, Q., Shi, J., Cao, B., et al. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00440 · Cited by 38
Tuuminen, R., Sahanne, S., & Loukovaara, S. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12363 · Cited by 38
Bangalore, S. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3339 · Cited by 40
Erdine, S. E., Ro, Y. S., Tse, H., Howes, L. G., Aguilar-Salinas, C., Chaves, H., Guindy, R. R., Chopra, P., Moller, R. A., Schou, I. M., et al. (2008) · Journal of Human Hypertension · doi:10.1038/jhh.2008.114 · Cited by 35
Lipids, lipid-lowering therapy and diabetes complications
Valensi, P. E., & Picard, S. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.10.001 · Cited by 38
Rodrigues, T. D. C., Pecis, M., Canani, L. H. S., Schreiner, L. R., Kramer, C. K., Biavatti, K., Macedo, B., Esteves, J., & de Azevedo, M. J. (2010) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302010000100019 · Cited by 36
Application of supercritical fluids in cholesterol extraction from foodstuffs: a review
Pourmortazavi, S. M., Saghafi, Z., Ehsani, A., & Yousefi, M. (2018) · Journal of Food Science and Technology · doi:10.1007/s13197-018-3205-z · Cited by 36
Therapies for diabetic dyslipidaemia
Bell, D. S. H., Badarin, F. J. A., & O’Keefe, J. H. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01342.x · Cited by 36
Prevalence of Metabolic Syndrome and its Components in Patients With Acute Coronary Syndrome
Jover, A., Corbella, E., Muñoz, A., Millán, J., Pintó, X., Mangas, A., Zúñiga, M., Pedro‐Botet, J., & Mijares, A. H. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.03.009 · Cited by 35
Wasko, B. M., Smits, J. P., Shull, L. W., Wiemer, D. F., & Hohl, R. J. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m016089 · Cited by 35
Enas, E. A., Kuruvila, A. T., Khanna, P., Pitchumoni, C. S., & Mohan, V. (2013) · Europe PMC (PubMed Central) · Cited by 34
Fenwick, E., Xie, J., Man, R. E. K., Sabanayagam, C., Lim, L. L., Rees, G., Wong, T. Y., & Lamoureux, E. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180252 · Cited by 36
Trévisan, L., Cautela, J., Resseguier, N., Laine, M., Arquès, S., Pinto, J., Orabona, M., Barraud, J., Peyrol, M., Paganelli, F. F., et al. (2017) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2017.05.006 · Cited by 34
Cardiovascular drugs that increase the risk of new-onset diabetes
Ong, K. L., Barter, P. J., & Waters, D. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2013.12.025 · Cited by 33
Self-citationJones, P. H. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.074 · Cited by 32
Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects
Mijares, A. H., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.02.002 · Cited by 31
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Tunnicliffe, D. J., Palmer, S. C., Cashmore, B. A., Saglimbene, V. M., Krishnasamy, R., Lambert, K., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub3 · Cited by 39
Ginsberg, H. N., & MacCallum, P. R. (2009) · Journal of Clinical Hypertension · doi:10.1111/j.1559-4572.2009.00060.x · Cited by 32
Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis
Zhou, Y., Yuan, Y., Cai, R., Huang, Y., Xia, W., Yue, Y., Wang, P., Wei, Q., & Wang, S. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.810210 · Cited by 31
Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence
Gupta, K. K., Ali, S., & Sanghera, R. S. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0123-0 · Cited by 35
Pharmacological interventions for heart failure in people with chronic kidney disease
Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., Palmer, S. C., Tonelli, M. A., Strippoli, G. F., & Ravani, P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466.pub2 · Cited by 33
Kataoka, Y., Shao, M., Wolski, K., Uno, K., Puri, R., Tuzcu, E. M., Nissen, S. E., & Nicholls, S. J. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312437931 · Cited by 30
Metadata
- Authors
- Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., Waters, D., & for the Treating to New Targets Investigators
- Affiliations
- University of Glasgow (GB)
- The University of Sydney (AU)
- Universitat de València (ES)
- University of California, San Francisco (US)
- Inserm (FR)
- The University of Texas at San Antonio Health Science Center (US)
- George Washington University Hospital (US)
- Pfizer (United States) (US)
- SUNY Downstate Health Sciences University (US)
- The University of Texas Southwestern Medical Center (US)
- San Francisco General Hospital (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-06-01
- Volume
- 29
- Issue
- 6
- Pages
- 1220-1226
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2160390128
- Cited by
- 525
- References
- 27
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 13 · 2023: 16 · 2022: 10 · 2021: 10 · 2020: 18 · 2019: 21 · 2018: 26 · 2017: 16 · 2016: 25 · 2015: 25 · 2014: 33 · 2013: 35 · 2012: 37
- FWCI
- 47.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- atorvastatin, intensive lipid-lowering therapy, LDL cholesterol lowering, coronary artery disease, diabetes mellitus, major adverse cardiovascular events, cardiovascular risk reduction, statin dose comparison
- MeSH terms
- Atorvastatin, Aged, Blood Pressure, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Dose-Response Relationship, Drug, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Triglycerides, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
